Investigational drug study for Multiple Myeloma

Trial ID:
IRB-17-6943
Anuj Mahindra, MD
The purpose of this study is to test the safety of an experimental drug called atezolizumab when given in combination with other standard drugs (daratumumab, pomalidomide and/or dexamethasone) at different dose levels in patients with Multiple Myeloma who have not responded to previous treatment. All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.

Inclusion Criteria

  • Be 18 years of age or older
  • Be diagnosed with Multiple Myeloma and have received at least one prior line of therapy
  • Be willing and able to undergo bone marrow aspiration and biopsy at the start of and during the study.
  • Meet all other eligibility criteria

Exclusion Criteria

  • Have had other cancers within 2 years (certain breast, cervical, skin or prostate are allowed).
  • Have cancer pain not able to be controlled by medication.
  • Be pregnant or planning to become pregnant.

Additional Info

  • Atezolizumab and daratumumab are both immunotherapy drugs that may help your immune system stop or reverse the growth of tumors.
  • Daratumumab, lenalidomide, and pomalidomide are all approved by the FDA for the treatment of multiple myeloma. Atezolizumab is investigational and has not been approved by the FDA.

Contact Info: